This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Gonadotroph Adenomas
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine if administration of pasireotide LAR for one year to three patients with gonadotroph adenomas and elevated serum FSH concentrations will reduce the serum follicle-stimulating hormone (FSH) to normal and reduce the adenoma size.

Provided treatments

  • Drug: pasireotide LAR
Tris trial is registered with FDA with number: NCT00929669. The sponsor of the trial is University of Pennsylvania and it is looking for 2 volunteers for the current phase.
Official trial title:
Effect of Pasireotide LAR on Gonadotroph Adenomas: A Pilot Study